MARKET

LAEKF

LAEKF

Laekna Inc.
OTCPK
2.000
NaN%
Closed 09:30 07/17 EDT
OPEN
--
PREV CLOSE
2.000
HIGH
--
LOW
--
VOLUME
--
TURNOVER
--
52 WEEK HIGH
7.30
52 WEEK LOW
2.000
MARKET CAP
815.47M
P/E (TTM)
-20.5339
1D
5D
1M
3M
1Y
5Y
1D
Reported Earlier, Laekna Secures FDA IND Approval For LAE120, Advancing Oncology Pipeline And Global Expansion With Lilly Partnership
Benzinga · 03/04 06:31
About LAEKF
Laekna Inc is an investment holding company mainly engaged in the discovery, development and commercialization of innovative therapies for cancer, liver diseases and obesity. The Company is still in the research and development stage. The Company's pipeline products include Afuresertib (LAE002), LAE001, LAE109, LAE111, LAE112, LAE113, LAE117, LAE118, LAE119, LAE102, LAE103, LAE104, LAE105, LAE106, LAE120, LAE123, and others. The Afuresertib is an adenosine triphosphate (ATP) competitive AKT inhibitor. The LAE001 is an androgen synthesis inhibitor that can inhibit CYP17A1 and CYP11B2 at the same time. The Company mainly conducts business in the Chinese, America, European, Korean, and other markets.

Webull offers Laekna Inc stock information, including OTCPK: LAEKF real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, LAEKF stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading LAEKF stock methods without spending real money on the virtual paper trading platform.